Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
Date:2/19/2009

-to-market unrealized gain on a deal-contingent foreign currency option contract that was entered into for the then pending acquisition of the former Merck Generics business, as well as the loss of $57.2 million on the early repayment of debt as discussed above.

EBITDA for the quarter ended Dec. 31, 2008, which is defined as net income (loss) (excluding minority interest and income from equity method investees) plus income taxes, interest expense, depreciation and amortization, was $142.3 million. After adjusting for certain non-recurring and non-cash items as further discussed below, adjusted EBITDA was $304.2 million. Comparable EBITDA and adjusted EBITDA amounts for the twelve months ended Dec. 31, 2008, were $838.3 million and $1.03 billion, respectively.

Non-GAAP Financial Measures

Mylan is disclosing non-GAAP financial measures when providing financial results. Primarily due to acquisitions, Mylan believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with accounting principles generally accepted in the United States (GAAP). In addition to disclosing its financial results determined in accordance with GAAP, Mylan is disclosing non-GAAP results that exclude items such as amortization expense and other costs directly associated with the acquisitions as well as certain other non-recurring and non-cash expenses in order to supplement investors' and other readers' understanding and assessment of the company's financial performance because the company's management uses these measures internally for forecasting, budgeting and measuring its operating performance. In addition, the company believes that including EBITDA and supplemental adjustments applied in presenting adjusted EBITDA is appropriate to pr
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Inc. (Nasdaq: NPSP ) announced today that ... and chief,executive officer-elect is scheduled to present at ... Miami on Wednesday, March,19, 2008 at 3:15 p.m. ... live,webcast with a replay available approximately 24 hours ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ... focused on,endocrine therapy and oncology, today announced ... Senior Vice President, Administrative & Legal,Affairs and ... position of,Vice President and Chief Financial Officer ...
... 29 Alfacell Corporation,(Nasdaq: ACEL ) today announced ... 11 a.m. EST on Friday, March 7. During the ... Kenyon, chief operating,officer and chief financial officer, will present ... quarter 2008, ended January 31,2008., To participate in ...
Cached Biology Technology:AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs 2Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast 2
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... release is available in German . ... plant introductions than extinctions, plant communities of many European ... occurring more frequently, whereas rare species are becoming extinct. ... becoming increasingly similar, but also the phylogenetic relations between ...
... The sequences of nonsense DNA that interrupt genes could ... than previously thought, according to a recent Science report ... biologists. Their study of the model organism ... demonstrate the colonization of a single lineage by "introns," ...
... 10, 2009 Arup K. SenGupta, Ph.D., a professor ... in Bethlehem, Pa., has been chosen to receive a ... the American Chemical Society, is given to individuals who ... health through their work in the chemical and related ...
Cached Biology News:Europe's flora is becoming impoverished 2Europe's flora is becoming impoverished 3Introns: A mystery renewed 2Introns: A mystery renewed 3Introns: A mystery renewed 4
... Gene silencing experiments often call for ... NeoFX Transfection Agent refines siRNA transfection ... NeoFXs lipid-based formulation can be used ... they are subcultured without increased ...
Kit for BASE20/50 dual control unit, includes mounting plate, HOLDER50T, HEATERPAD50, SRTDX temperature probe(s)....
... CHEMICON® CaspaTag™ Pan-Caspase In Situ Assay Kit ... active caspases in cells undergoing apoptosis. The ... for use in diagnostic or therapeutic procedures. ... use a novel approach to detect active ...
... nM is available for in vivo ... in: Z. Hassani, G.-F. Lemkine, P. Erbacher, ... B.-A. Demeneix. Lipid-mediated siRNA delivery down regulates ... at picomolar levels. J. Gene Med., 2005, ...
Biology Products: